2026 Q2 -tulosraportti
18 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·11 min sittenNovo AI is now ready to go. Gefion 2.0 with over 1500 nvidea chips. Will we see gefion compete against openai and antrophic?
·36 min sittenA good 2000 more are taking the pill. How many have switched from another product among the 135000 users. I think that the largest share are already users of a Novo product.The latest data points to a total number of prescriptions for Novo's weight loss tablet of 135.566 in week 33 compared to 133.143 the week before.
·49 min sitten · MuokattuI will stay 80 % in, if in the coming week we see 314, through quick movement through 304 (close above), 307-309 and not least close above 312 in the coming week… If there is just REALLY some positive news for Novo in the coming week, then we should head towards 323, with a new bottom at 314. (Currently fills 25% in my pot) Solely when I look into the cup this morning. Good dayYou should use Novo in USA as guidance. Weak USD changes the price of Novo in ddk. And you should also take dividend payment into account. I don't think there is much upside. If one takes weak USD and dividend payment into the calculation, it's around 310. I sold my bull certificates at 310 in connection with sad news regarding Novo's pipeline. Bought 300 same day. But good luck.
·1 t sittenSunday reading on the pill battle between Novo and Lilly: UPDATE: Aug. 21, 2026 After a one-week hiccup, Novo Nordisk’s Wegovy pill regained its momentum last week with its largest prescription rate since it was launched in January. There were more than 176,000 prescriptions for the pill in the period, according to data gathered by IQVIA and cited in a note by Citi. The oral treatment now accounts for 35% of total Wegovy prescriptions, which is up from 33% the previous week, analysts from Citi said in their weekly update to investors. Meanwhile, Eli Lilly’s oral GLP-1 Foundayo, which had been on a steady five-week climb, backtracked, with a drop-off from 38,928 prescriptions in the prior period to 36,620 in the latest week. The movements for the two oral treatments contributed to overall market share adjustments for the companies' diabetes and obesity medicines. While Lilly made a 0.1% gain to 56.7%, Novo increased its market share by 0.3% to 37.1%. UPDATE: Aug. 14, 2026 Despite its leading position in the oral GLP-1 market, Novo Nordisk's Wegovy pill seems to be hitting a market share ceiling. For months now, shares of total prescriptions for Wegovy pill within the entire Wegovy franchise have struggled to break through the one-third mark. While share of oral semaglutide within all Wegovy scripts hit 35% in our previous update, it fell back to 33% last week, as Wegovy pill scripts dropped to about 163K, down from a high of roughly 172K the week prior, according to IQVIA data cited by Citi. Total Wegovy scripts, including the original injectable, declined 1.1% sequentially to about 495.5K. As a result, Novo yielded about 0.7 percentage point in obesity market share to Eli Lilly's Zepbound last week based on the IQVIA data. The split stood at 39.9% and 60.1% between Novo and Lilly. Meanwhile, Lilly's Foundayo continued its upward trajectory with 38,928 total scripts, representing another step up from its previous record of 34,219 set the week prior. UPDATE: Aug. 7, 2026 Prescriptions for Eli Lilly's Foundayo continue to build, jumping 16% sequentially to 34,219 the previous week, according to IQVIA data cited by Citi. The oral GLP-1 med has been on a roll lately as it appears to celebrate four weeks of consecutive growth in total scripts. However, as Citi noted, there's still a potential gap in IQVIA's capture of telehealth data, and it's not clear how much of the scripts growth was from IQVIA getting better at including those data, or, if the actual growth was much faster in telehealth channels. This week, Lilly's reported Foundayo sales for the second quarter—$98 million in total, including $67 million in the U.S.—disappointed many. As CEO David Ricks noted on an earnings call, Lilly began broad direct-to-consumer marketing to raise consumer awareness after securing commercial access across the three major pharmacy benefit managers in June. Besides, The Medicare GLP-1 Bridge program went live on July 1, offering coverage for certain weight-loss medications, including Foundayo, for a $50 copayment per month. Ilya Yuffa, president of Lilly USA and global customer capabilities, said the company is "starting to see an inflection point on Foundayo now." As for Novo Nordisk's Wegovy pill, total scripts recorded by IQVIA have been largely flat with small upticks in the past two weeks, having reached roughly 172K in the previous week. The oral version of semaglutide now makes up 35% of total Wegovy scripts, which take up about 40.6% of the U.S. obesity market share, as Lilly's Zepbound remains the leader. source: Fierce Pharma
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
18 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 min sittenNovo AI is now ready to go. Gefion 2.0 with over 1500 nvidea chips. Will we see gefion compete against openai and antrophic?
- ·36 min sittenA good 2000 more are taking the pill. How many have switched from another product among the 135000 users. I think that the largest share are already users of a Novo product.The latest data points to a total number of prescriptions for Novo's weight loss tablet of 135.566 in week 33 compared to 133.143 the week before.
- ·49 min sitten · MuokattuI will stay 80 % in, if in the coming week we see 314, through quick movement through 304 (close above), 307-309 and not least close above 312 in the coming week… If there is just REALLY some positive news for Novo in the coming week, then we should head towards 323, with a new bottom at 314. (Currently fills 25% in my pot) Solely when I look into the cup this morning. Good dayYou should use Novo in USA as guidance. Weak USD changes the price of Novo in ddk. And you should also take dividend payment into account. I don't think there is much upside. If one takes weak USD and dividend payment into the calculation, it's around 310. I sold my bull certificates at 310 in connection with sad news regarding Novo's pipeline. Bought 300 same day. But good luck.
- ·1 t sittenSunday reading on the pill battle between Novo and Lilly: UPDATE: Aug. 21, 2026 After a one-week hiccup, Novo Nordisk’s Wegovy pill regained its momentum last week with its largest prescription rate since it was launched in January. There were more than 176,000 prescriptions for the pill in the period, according to data gathered by IQVIA and cited in a note by Citi. The oral treatment now accounts for 35% of total Wegovy prescriptions, which is up from 33% the previous week, analysts from Citi said in their weekly update to investors. Meanwhile, Eli Lilly’s oral GLP-1 Foundayo, which had been on a steady five-week climb, backtracked, with a drop-off from 38,928 prescriptions in the prior period to 36,620 in the latest week. The movements for the two oral treatments contributed to overall market share adjustments for the companies' diabetes and obesity medicines. While Lilly made a 0.1% gain to 56.7%, Novo increased its market share by 0.3% to 37.1%. UPDATE: Aug. 14, 2026 Despite its leading position in the oral GLP-1 market, Novo Nordisk's Wegovy pill seems to be hitting a market share ceiling. For months now, shares of total prescriptions for Wegovy pill within the entire Wegovy franchise have struggled to break through the one-third mark. While share of oral semaglutide within all Wegovy scripts hit 35% in our previous update, it fell back to 33% last week, as Wegovy pill scripts dropped to about 163K, down from a high of roughly 172K the week prior, according to IQVIA data cited by Citi. Total Wegovy scripts, including the original injectable, declined 1.1% sequentially to about 495.5K. As a result, Novo yielded about 0.7 percentage point in obesity market share to Eli Lilly's Zepbound last week based on the IQVIA data. The split stood at 39.9% and 60.1% between Novo and Lilly. Meanwhile, Lilly's Foundayo continued its upward trajectory with 38,928 total scripts, representing another step up from its previous record of 34,219 set the week prior. UPDATE: Aug. 7, 2026 Prescriptions for Eli Lilly's Foundayo continue to build, jumping 16% sequentially to 34,219 the previous week, according to IQVIA data cited by Citi. The oral GLP-1 med has been on a roll lately as it appears to celebrate four weeks of consecutive growth in total scripts. However, as Citi noted, there's still a potential gap in IQVIA's capture of telehealth data, and it's not clear how much of the scripts growth was from IQVIA getting better at including those data, or, if the actual growth was much faster in telehealth channels. This week, Lilly's reported Foundayo sales for the second quarter—$98 million in total, including $67 million in the U.S.—disappointed many. As CEO David Ricks noted on an earnings call, Lilly began broad direct-to-consumer marketing to raise consumer awareness after securing commercial access across the three major pharmacy benefit managers in June. Besides, The Medicare GLP-1 Bridge program went live on July 1, offering coverage for certain weight-loss medications, including Foundayo, for a $50 copayment per month. Ilya Yuffa, president of Lilly USA and global customer capabilities, said the company is "starting to see an inflection point on Foundayo now." As for Novo Nordisk's Wegovy pill, total scripts recorded by IQVIA have been largely flat with small upticks in the past two weeks, having reached roughly 172K in the previous week. The oral version of semaglutide now makes up 35% of total Wegovy scripts, which take up about 40.6% of the U.S. obesity market share, as Lilly's Zepbound remains the leader. source: Fierce Pharma
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
18 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 min sittenNovo AI is now ready to go. Gefion 2.0 with over 1500 nvidea chips. Will we see gefion compete against openai and antrophic?
- ·36 min sittenA good 2000 more are taking the pill. How many have switched from another product among the 135000 users. I think that the largest share are already users of a Novo product.The latest data points to a total number of prescriptions for Novo's weight loss tablet of 135.566 in week 33 compared to 133.143 the week before.
- ·49 min sitten · MuokattuI will stay 80 % in, if in the coming week we see 314, through quick movement through 304 (close above), 307-309 and not least close above 312 in the coming week… If there is just REALLY some positive news for Novo in the coming week, then we should head towards 323, with a new bottom at 314. (Currently fills 25% in my pot) Solely when I look into the cup this morning. Good dayYou should use Novo in USA as guidance. Weak USD changes the price of Novo in ddk. And you should also take dividend payment into account. I don't think there is much upside. If one takes weak USD and dividend payment into the calculation, it's around 310. I sold my bull certificates at 310 in connection with sad news regarding Novo's pipeline. Bought 300 same day. But good luck.
- ·1 t sittenSunday reading on the pill battle between Novo and Lilly: UPDATE: Aug. 21, 2026 After a one-week hiccup, Novo Nordisk’s Wegovy pill regained its momentum last week with its largest prescription rate since it was launched in January. There were more than 176,000 prescriptions for the pill in the period, according to data gathered by IQVIA and cited in a note by Citi. The oral treatment now accounts for 35% of total Wegovy prescriptions, which is up from 33% the previous week, analysts from Citi said in their weekly update to investors. Meanwhile, Eli Lilly’s oral GLP-1 Foundayo, which had been on a steady five-week climb, backtracked, with a drop-off from 38,928 prescriptions in the prior period to 36,620 in the latest week. The movements for the two oral treatments contributed to overall market share adjustments for the companies' diabetes and obesity medicines. While Lilly made a 0.1% gain to 56.7%, Novo increased its market share by 0.3% to 37.1%. UPDATE: Aug. 14, 2026 Despite its leading position in the oral GLP-1 market, Novo Nordisk's Wegovy pill seems to be hitting a market share ceiling. For months now, shares of total prescriptions for Wegovy pill within the entire Wegovy franchise have struggled to break through the one-third mark. While share of oral semaglutide within all Wegovy scripts hit 35% in our previous update, it fell back to 33% last week, as Wegovy pill scripts dropped to about 163K, down from a high of roughly 172K the week prior, according to IQVIA data cited by Citi. Total Wegovy scripts, including the original injectable, declined 1.1% sequentially to about 495.5K. As a result, Novo yielded about 0.7 percentage point in obesity market share to Eli Lilly's Zepbound last week based on the IQVIA data. The split stood at 39.9% and 60.1% between Novo and Lilly. Meanwhile, Lilly's Foundayo continued its upward trajectory with 38,928 total scripts, representing another step up from its previous record of 34,219 set the week prior. UPDATE: Aug. 7, 2026 Prescriptions for Eli Lilly's Foundayo continue to build, jumping 16% sequentially to 34,219 the previous week, according to IQVIA data cited by Citi. The oral GLP-1 med has been on a roll lately as it appears to celebrate four weeks of consecutive growth in total scripts. However, as Citi noted, there's still a potential gap in IQVIA's capture of telehealth data, and it's not clear how much of the scripts growth was from IQVIA getting better at including those data, or, if the actual growth was much faster in telehealth channels. This week, Lilly's reported Foundayo sales for the second quarter—$98 million in total, including $67 million in the U.S.—disappointed many. As CEO David Ricks noted on an earnings call, Lilly began broad direct-to-consumer marketing to raise consumer awareness after securing commercial access across the three major pharmacy benefit managers in June. Besides, The Medicare GLP-1 Bridge program went live on July 1, offering coverage for certain weight-loss medications, including Foundayo, for a $50 copayment per month. Ilya Yuffa, president of Lilly USA and global customer capabilities, said the company is "starting to see an inflection point on Foundayo now." As for Novo Nordisk's Wegovy pill, total scripts recorded by IQVIA have been largely flat with small upticks in the past two weeks, having reached roughly 172K in the previous week. The oral version of semaglutide now makes up 35% of total Wegovy scripts, which take up about 40.6% of the U.S. obesity market share, as Lilly's Zepbound remains the leader. source: Fierce Pharma
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt